Spark Therapeutics Inc. has earned a place in the pharma history books on two fronts, as the first drug maker to secure a gene therapy approval from FDA and the first company to develop a treatment for blindness. But it remains to be seen whether it reaches another first – a $1m price tag.
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Spark's gene therapy for patients with an inherited form of blindness will be available in the US late in the first quarter, but on the big question – whether it will cost $1m for the one-time treatment – Spark would not say.
More from New Products
More from Scrip
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.